In today’s era focus is on functional foods for health enrichment with minimum efforts. Interest in self-care and integrative medicine, coupled with foods that promote health, apart from providing basic nutrition has emerged in recent times. Historically, yoghurt is probably the oldest example of fermented food which was used to support intestinal and overall health. In ancient Indian societies, it was a common practice to consume a yogurt drink called Lassi before-dinner and a small serving of curd at the end of meal. These Indian traditions assumed of using sour milk are perhaps the earliest examples of a probiotic delivery system to our body. The origin of word ‘Probiotic’ is traced to Greek language, ‘pro bios’ which means ‘for life’. Its opposite ‘antibiotic’ is more familiar meaning ‘against life’. Probiotics were first described in 2002 by the authorities from the Food and Agriculture Organization of the United Nations and the World Health Organization. The definition was revised by the International Scientific Association in 2013¹. The definition reveals that, “probiotics are live strains of strictly selected microorganisms which, when administered in adequate amounts, confer a health benefit on the host.” The intestinal tract of new-born is sterile at birth, with time and age it gets colonized by number of organisms from breast milk, formula fed milk, mother’s vagina, diet, environment etc. A vast number of factors affect colonization of intestine by bacteria. The very first organisms to colonize in the new-born are Escherichia coli, Clostridium spp., Streptococcus spp., Lactobacillus spp., Bacteroides spp., and Bifidobacterium spp. Bifidobacterium which colonizes in highest numbers gets excreted in faeces of breast-fed infants². The composition of flora changes overtime depending upon diet and medical emergencies. The number of bacteria present in large intestine is upto 10¹¹  colony-forming units/g. The healthful human gut is conquered by Bacteroides, Firmicutes and Actinobacteria, each comprising a unique bacterial composition of the stool³. The gut microflora plays a significant role in human well-being, not only due to its contribution in the digestion progression but also for its critical role in the maturity of the gut and the immune system. The human gastrointestinal tract (GIT) comprises an extraordinarily complex and active microbial community which in particular for every individual depends on environmental and genetic factors⁴. The gastrointestinal flora is increasingly being used for prevention and treatment of several disorders like lactose intolerance, allergies, colon cancer, Irritable bowel syndrome (IBS), Osteoarthritis and diseases like Clostridium difficile (CD) infection and diarrhoea^5-7. Knight and his coworkers showed presence of probiotics in faeces after three days of oral administration therapy with Synbiotic 2000 Forte which is a mixture of probiotics able to survive in the stomach and gut. Synbiotic 2000 Forte consists of combination of 10¹¹ colony forming units of each of four probiotics, Lactobacillus paracasei 25%, L. plantarum 25%, Leuconostoc mesenteroides 25%, Pediococcus pentosaceus 25% with bioactive fibres, oat bran, 2.5 g, pectin, 2.5 g, resistant starch, 2.5 g, inulin, 2.5 g (total weight, 10 g)⁸.

Faecal microbiota transplant (FMT) is a technique in which Faecal matter from a healthful donor is mixed with saline solution and is placed into a recipient with chronic, serious, or complicated Clostridium difficile (CD) infection. The primary purpose of FMT is to re-establish a healthy microbiota balance that facilitates the resistance to growth of pathogenic bacteria, thus reducing the chance of recurrent colitis and dysentery.

Criteria for selection of Probiotics
The source of probiotic culture often is of human origin like human faces or breast milk, animal source like fresh raw milk or fermented food. As per the guidelines of FAO/WHO 2002 probiotic tests which are currently used in vitro for screening of cultures are

1. Resistance to gastric acidity
2. Bile acid resistance
3. Adherence to mucus and/or human epithelial cells and cell lines
4. Antimicrobial activity against potentially pathogenic bacteria
5. Capability to reduce pathogen adhesion to surfaces
6. Bile salt hydrolase activity
7. Resistance to spermicides (applicable to probiotics for vaginal use)

Probiotics commonly provided through dairy products improve the transit tolerance of bacteria. Other delivery systems for probiotics are meat and fish-based products, confectionery, table olives, soya and cereal-containing products, edible spreads, artichokes (European plant) etc.⁹ Artichokes or olives furnish nutrients to enable bacterial survival throughout shelf storage. The mode of action Probiotics is by altering the local environment of the gut, producing antimicrobial compounds like bacteriocins to be used against pathogens. Hence a strict selection criterion is employed to obtain functional probiotic strains. Most of the probiotics are a mixture of strains of Lactobacilli and (or) Streptococci and Bifidobacterium. Some commercial products contain strains in combination with others leading to enhanced effect. The probiotic strain should be of host origin, well characterized, able to colonize by surviving the rigors of the digestive tract and, biologically active against the target as well as stable and flexible for commercial production and distribution¹⁰.

Desirable Characteristics for Potential Probiotic Strain
To be defined as probiotic, a microbe must possess a following set of criteria¹¹

• Exert a beneficial effect on host
• Nontoxic and non-infective
• Precise taxonomic classification
• Normal inhabitant of species
• Able to survive, proliferate, and having metabolic activity in the target site, which include
• Resistance to gastric and bile salts
• Adherence to intestinal epithelial cell lining
• Capacity to compete with resistant flora
• Produce antimicrobial substances
• Stabilize intestinal microflora
• Acceptable to host’s immune response
• In vivo antagonism towards pathogenic bacteria
• Genetically stable
• Amenability of strain
• Stability of desired characteristics during processing, storage, and delivery
• Feasibility at highest population
• Good shelf life in food
• Biosafety, the strain used should belong to, Generally Regarded as Safe (GRAS) category

Bile Tolerance
Survival in gastrointestinal tract requires the probiotic strain to be able to resist low pH due to gastric acid, bile and gastric enzymes. Acid and bile stability are significant among the other criteria used in selection probiotic microbes¹². The bile salts act as biological detergent which emulsifies and solubilizes fats. This confers powerful antimicrobial properties to bile and plays an significant role in the body’s physico-chemical defence system¹³. Probiotics like Lactobacilli¹⁴, Bifidobacteria¹⁵, Enterococcus¹⁶, Saccharomyces¹⁷ assimilate cholesterol and deconjugate bile acids, leading to a decrease in serum cholesterol. Bile salts are produced in liver from cholesterol and secreted as amino acid conjugates into the duodenum. The exact mechanism by which probiotics lower serum cholesterol is unclear but it is thought that cholesterol elimination from culture media is a result of formation of cholesterol with free bile acids in the media due to activity of bile salt hydrolase enzyme. Enterococcus faecium WEFA23 isolated from human infants has Glycodeoxycholic acid (GDCA) hydrolase activity and cholesterol-removal ability in an environment containing 3% bile salt¹⁸.

Acid Tolerance
The initial screening of probiotics includes tolerance of cultures to gastric acid. Acid tolerance of probiotics is also essential for production of probiotic products like fermented foods. Hence acid tolerance is primarily important in screening for probiotic cultures¹². A healthy adult human stomach secretes about 1.5 litres of gastric acid daily. To survive in the stomach, probiotic strains must bear the acidic conditions of the stomach pH 1.5 to 3.5. The presence of prebiotic substances carried by artichokes or olives such as inulin, contribute efficiently to favour the growth of indigenous lactobacilli and/or bifidobacteria⁹. Artichokes when preserved in brine of pH 3.5, enriched with L. plantarum ITM21B or L. paracasei IMPC2, no considerable decrease in the bacterial population was observed for either strain after 30 days of storage⁹. In order to survive in the stomach, probiotic strains must tolerate the acidic pH of the stomach i.e. about 1.5 to 3.5. It is assumed that acid tolerance of Bifidobacteria depends on H⁺-ATPase activity¹⁹. B. animalis and B. lactis are more acid tolerant among the Bifidobacteria²⁰ having higher H⁺-ATPase activity²¹.

Antipathogenic activity
One selection criterion for probiotics is the production of antimicrobial substances, which exert a beneficial effect on host. Lactic acid and acetic acid producing probiotics decrease the pH of the lumen creating unfavorable conditions for pathogens²². Along with bacteriocins, LAB produce organic acids, such as lactic and acetic acids, hydrogen peroxide, or diacetyl having antimicrobial potential²³. Probable mechanism by which probiotics exhibit antipathogenic effect is shown in Fig. 1. Other antimicrobial compounds secreted by LAB and Bifidobacteria against dermal pathogen Staphylococcus aureus are lactic acid, acetic acid, hydrogen peroxide, and diacetyl²⁴. Thus, probiotic strains that are able to colonize in the digestive tract play a significant role in the release of antimicrobial compounds which, by their highly inhibitory action, regulates the composition of normal flora in the digestive tract. An imbalance in normal intestinal flora is an obvious reason of establishment and growth of enteropathogens like Salmonella, Campylobacter, Escherichia coli and others. A commercially available bifidus yoghurt and oral preparation of Bifidobacteria is used to eliminate Campylobacterium jejuni from stools of children suffering from enteritis²⁵. Bifidobacterium animalis lactis BB-12 and Enterococcus faecium used as adjuvant in therapy, are clinically proven to eradicate Helicobacter pylori (Hp) infection with reduction in incidences side effects, mainly diarrhea²⁶. Probiotics also help us in fighting against common food borne pathogens like Salmonella spp., S. aureus, Listeria monocytogenes, E. coli, Shigella spp., Campylobacter spp. along with, species of Pseudomonas, Bacillus and Serratia.^27-29.

Adherence to mucus and human epithelial cells and cell lines
Capability to adhere to human intestinal surfaces is one of the key selection criteria for probiotic bacteria. Adhesion of probiotics to intestinal wall helps to maintain normal flora in the gut thus influencing the host’s microbial balance and gastrointestinal system. To study in vitro adhesive properties of probiotics enterocyte like Caco-2 tissue culture cells³⁰, intestinal mucus and human ileostomy glycoproteins are currently used³¹. Intestinal mucus protects mucosal lining from microbes, provides initial binding site and matrix on which microbes adhere, also serving as a nutrient source to them. B. longum and B. catenulatum adhere to human intestinal mucus and inhibit competitively pathogens like Salmonella enterica serovar typhimurium, E. coli, L. monocytogenes, Enterobacter sakazakii, and Clostridium difficile from adhering to human intestinal mucus³². L. acidophilus CRL1259L, L. crispatus CRL 1266, L. paracasei CRL 1289 adhere competitively to vaginal epithelial cells (VEC) and exclude urogenital pathogens like S. aureus. L. acidophilus 1259 and L. paracasei CRL 1289 competitively excluding Group B Streptococci³³. L. delbrueckii spp. bulgaricus (LDB B-30892) substantially lowers the adhesion of C. difficile to the human colonic Caco-2 cells³⁴. Live and heat killed strain of L. rhamnosus CNCM-I-3698 and L. farciminis CNCMI-3699 respectively, are adherent to intestinal matrix models and their high co-aggregation property has been proved in vitro which eliminates Campylobacter spp.³⁵

In addition to adhesion, another important mechanism for pathogen exclusion by probiotics is aggregation. Probiotics also exert capacity to aggregate among themselves (auto-aggregation), with other probiotics and with pathogens (co-aggregation). Co-aggregation leads to the formation of a protective barrier for intestinal epithelium, inhibiting colonization by harmful pathogens. Measuring co-aggregation of pathogens serves as a preliminary screening to identify potentially probiotic organisms³⁶.

Biosafety
Probiotics are not under regulation of the US Food and Drug Administration (FDA) as they are considered to be dietary rather than a therapeutic product. They are easily available in market and can be bought without prescription. Probiotics are consumed as health supplements rather than therapy. Some may experience gas and bloating after consumption³⁷. With respect to safety consideration of probiotic microorganisms, it is recommended that probiotic microorganisms are strictly free of genetic resistance determinants like plasmid, which encode resistance against clinically used antibiotics³⁸. Such probiotic are generally regarded as safe (GRAS) and can be used safely³⁹. Available safety data regarding the broad range of probiotic strains added to food or feed are periodically compiled by the European Food Safety Authority (EFSA)⁴⁰.

Health Benefits
There are numerous health benefits of probiotic organisms. Most probiotic strains of human origin are safe to use because they are commensals and exert rapid effects.

Gut microbiota
Gut microbiota (GM) is also called as “forgotten organ” which harbours 100 trillion bacteria, (fungi, archaea, and viruses) which are 10 times greater than the number of cells present in human body⁴¹. Intestine is an enormously multifaceted living system that protects the host strongly against external aggregations. The small intestine harbours a single dense mucus layer. In the colon, mucus is organized into two distinct layers, an outer loose layer, and an inner dense layer that is connected to the epithelium. The fast-increasing facultative anaerobes overgrow microbial community of the small intestine that tolerates the influences of bile acids and antimicrobials. Small intestine of humans contains Proteobacteria and Clostridium species. The cecum and colon of large intestine contains anaerobic fermentative polysaccharide catabolizing anaerobes belonging to families Bacteroidaceae and Clostridiaceae. Dominant organisms in the colon belong to Firmicute families, Lachnospiraceae and Ruminococcaceae. In stomach dominant organisms are Bacteroidetes families, Prevotellaceae, Bacteroidaceae, and Rikenellaceae⁴². As stated above, bacterial population is much higher in the colon as compared to the small intestine. The colon is colonized by bacterial families including Bacteriodaceae, Ruminococcaceae, Prevotellaceae, and Clostridiaceae (10¹¹–10¹²CFU/ml). Indigenous flora of stomach consist of species from the families Lactobacillaceae and Streptococcaceae in the epithelial layer. The gut microflora plays a key role against extrinsic bacteria through resistance to colonization. The homeostasis in gut can be due to dietary changes, antibiotic exposure, infections, disease states, and maturing. Aging was complemented with growing proportion of Bacteroides, Eubacterium and Clostridiaceae. Enterobacteriaceae was augmented in infant and aged people. There is age-related decrease in the performance of gut microbiota, as well as rise of inflammation and diseases, particularly for the aged people older than 90s⁴³.

FMT (Faecal microbiota transplantation): Faecal microbiota transplant (FMT), also well-known as stool transplant, is the practice of transplantation of faecal bacteria from a healthful donor into a recipient to reestablish normal flora in recipient⁴⁴. FMT is the known terminology which defines the infusion of distal faecal matter from a healthy donor into the Gastrointestinal tract of a recipient to re-establish healthy intestinal microflora⁴⁵. The therapeutic principle on which FMT works is microbes, their roles and the metabolites formed by them⁴⁶. The criterion of FMT is to improve intestinal imbalance by transporting stool comprising a stable, live, varied, and normal microbial community from a healthy donor or from well-defined colonic bacterial strains⁴⁶. FMT requires restoration of the microflora by establishing healthy bacterial flora via infusion of stool, e.g. via colonoscopy, enema, orogastric tube, or by mouth in the form of a capsule containing freeze-dried material, gained from a healthy donor. The constant antibiotic medication in patients leads to acute damage of normal intestinal microflora. Replacing the entire intestinal flora of recipient by healthy donor flora gets a donor-like flora composition with stabilization of its usefulness in the recipient. With a level of complexity like an organ, the gut is home to a intricate mixture of more than 1000 microbial varieties, which jointly harbour 100 times more genes than the human genome.

A healthy human gut microbiota comprises of a higher ratio of Bacteroides to Firmicutes and overall higher bacterial diversity⁴⁷. The gastrointestinal microbiome (GIM) may be subject to progressive or dietary compositional variations, antibiotic damage and super infections, like the C. diffcile infection (CDI). Changes in diet, administration of particular antibiotics, probiotics, or FMT may be utilized to rebuild dysbiosis or eradicate contagious pathogens, such as C. diffcile⁴⁵. Due to the increase in cases of community and hospital acquired CDI, elevated rates of recurrent CDI (projected 20–30% after a first and 50–60% after a third infection), high mortality (~29,000 deaths annually) in the USA, and the emergency for treatments not involving antibiotics gave birth to microbiome-based remedies⁴⁸. Pseudomembranous colitis (PMC) is a disease of the colon caused due to antibiotics or other agents upsetting the normal intestinal flora. Bacteroides sp. are absent in patient’s stool and are present after FMT when PMC is treated with FMT, indicating that colonization with Bacteroides sp. seems to be particularly crucial in maintaining normal bowel movement and increased resistance to Gastrointestinal infections⁴⁹. FMT was first used in 1950s by Mr. Ben Eiseman to treat his patients with antibiotic associated diarrhoea. Since then, it has been a highly effective strategy for treating CDI⁵⁰. After being successfully used in treatment of C. difficile, FMT can be used in cure of inflammatory bowel disease (IBD) which is a medical condition accounted as abdominal discomfort or pain and gut dysbiosis without pathological condition⁵¹. IBD is also a group of immune-mediated diseases mainly denoted by Ulcerative colitis (UC) and Crohn’s disease (CD). Traditional medication for IBD treatment involves the use of amino-salicylates, corticosteroids, thiopurines, folic acid antagonists, or biological treatments which only controls inflammation besides healing disease so that patients become intolerant to these remedies. Fecal microbiota transplantation (FMT) and probiotics have been discovered as promising candidates to re-create microbial balance in several immune-mediated illnesses such as IBD⁵². An analysis involving the treatment consequence of FMT and probiotic mixture VSL#3 the clinical amnesty and medical response did not fluctuate much⁵¹. The exact mechanism of effectiveness of FMT and the specific strains that confer this advantage remain undecided. It is stated that endoscopic FMT might be the first line to cure patients with severe CDI and its complications⁵³. FMT not only consistently eradicates CDI but also reestablishes the Faecal flora, which is the possible mechanism for the pathogen’s colonization and perseverance. In addition to CDI there are many other diseases which are treated by FMT (Table 1). After FMT treatment patients commonly experience symptoms like bloating, cramping, and/or constipation after few days following transplant. FMTs performed via colonoscopy have certain consequences associated with colonoscopy, such as unfavorable tranquilizer reaction and bowel perforation after the procedure⁵⁴. Probiotics are commonly administered in conjunction with antibiotics in order to replenish loss of normal flora. Oral administration of probiotics requires more time for normalization as compared to FMTs. There is a metabolic interconnection between the different microbial communities in gut to alleviate host immunity against pathogens. In this regard many physicians use a few individual species of ‘excellent microorganisms’ to treat antibiotic-induced acute dysbiosis⁴⁹. Probable mechanisms for FMT efficacy in treatment of CDI, comprises direct battle of C. difficile with commensal microbiota delivered by FMT, rebuilding of secondary bile acid metabolism in the colon and restoration of the gut barrier by stimulus of the mucosal immune system⁵⁵. In a controlled study an industrial preparation (Bio-25) available in market containing 11 species of common probiotic bacteria (variety of Lactobacilli, Bifidobacteria, Lactococcus lactis, and Streptococcus thermophilus) was fed daily to healthy human volunteers for 28 days. The fed probiotic bacteria were discovered in stool samples of all members until they were using the product⁵⁶ which led to a assumption that probiotics can be hypothetical target in FMT to boost the effectiveness of therapy. Oral administration of probiotic species Lactobacillus and Bifidobacterium for four to twelve weeks showed to be effective in treating constipation in Parkinsons Disease (PD)⁵⁷.

Table (1):
Diseases treated with FMT.

Analysis of microbes in FMT showed abundant number of genera, Bacteroides, Prevotella, Bifidobacterium, Faecalibacterium, and Lachnospiraceae present along with Escherichia, Shigella and Alistipes^58,46. Gut mucosal establishment of probiotics depends on the capability of probiotics to interact with local microbiome niches, which differ in their physiological properties along the gastrointestinal tract of the individual hence probiotics might solely be used in FMT. FMT provides number of microbes. Further research is needed on microbes and their products responsible for its health benefits. In addition to CDI there are many diseases which are treated by FMT.

Vitamin production
Probiotic bacteria have a positive effect on the immune system and the composition and operation of the gut microbiota¹¹. Human beings are unable to make riboflavin or vitamin B2 and fulfill it from dietary intake of milk and dairy products, fish and meat. Riboflavin deficiency is indigenous in populations who are vegetarian, lacking dairy products and meat⁷². The Probiotic lactic acid bacteria L. lactis flourish in absence of riboflavin. Based on the genome sequencing of L. lactis IL1403, it is shown to harbour all genes required for riboflavin biosynthesis (rib genes)⁷³. These micronutrients are used as a cofactor in several enzymatic reactions, as in case of vitamin B12⁷⁴. L. coryniformis subsp. coryniformis CRL 1001 can manufacture corrinoids with cobalamin action. HPLC and mass spectrometry analysis shows corrinoid produced is pseudo-cobalamin that has adenine like Coα-ligand instead 5, 6-dimethylbenzimidazole. This molecule is one of the forms of coenzyme B12 occurring in atmosphere⁷⁵. Vitamin B1 or Thiamine plays a significant role in amino acid metabolism, and is a rate limiting cofactor in production of neurotransmitter like dopamine, serotonin, gamma amino butyric acid (GABA), noradrenaline, and the hormone melatonin^72,76. The strains of Lactobacillus used in production of functional foods belong to the species L. acidophilus, L. casei, L. paracasei, L. plantarum, L. reuteri, and L. salivarius which are powerful folic acid producers⁸ . Folic acid plays an important role in purines and pyrimidines metabolism, hence, in DNA formation. With exception to other lactic acid bacteria L. plantarum in presence of para-aminobenzoic acid (PABA) produces folic acid in vivo in rats.

Though abundant source of vitamin K are green leafy vegetables, some individuals are deficient in vitamin K which plays a major role in blood clotting. L. lactis ssp. cremoris (three strains), L. lactis ssp. lactis (two strains), and Leuconostoc lactis are high manufacturers of quinone that synthesize higher than 230 nmol of quinones/g of dried cells⁷⁷.

Antibiofilm formation
Biofilms are microbially derived immobile communities characteristic of cells that are adjacent to a substratum, an interface, or to each other; are embedded in a self-produced matrix; and display an altered phenotype with regard to growth rate and transcription profile⁷⁸. Vibrio cholerae have ability to develop strong biofilms which is vital for its intestinal colonization⁷⁹. This is for the reason that; biofilm forming cells are more efficient in competing for limiting nutrients in the small intestine. Probiotic strains having both antimicrobial and anti-biofilm properties against V. cholerae are anticipated to be clinically better. Culture supernatant of Faecal lactobacilli isolates prevent the adherence of both V. cholerae and V. parahaemolyticus to the colonic epithelial cell line HCT-15 by more than 90%⁸⁰. EPS-producing L. plantarum WLPL04 screened from human breast milk acquire anti-adhesion characteristic and ability to displace, and inhibit E. coli O157, H7, P. aeruginosa CMCC10104, S. typhimurium ATCC13311, and S. aureus CMCC26003. This indicates that EPS secreted by L. plantarum WLPL04 possesses activity against biofilm formed by pathogens⁸¹.

Anti-obesity Properties
The population of overweight people is increasing worldwide. Obesity is one of the defined health troubles and is considered as the most predominant form of malnutrition⁸², which increases the frequency of obesity-related complications and the global problem of illness. Obesity is defined as an accumulation of unnecessary fat that weakens health. Excessive intake of calories is responsible for chronic diseases like obesity, gallbladder disease, coronary heart disease (CHD), hypertension, osteoarthritis (OA), type 2 diabetes mellitus, hyperlipidaemia, certain cancers and cardiovascular diseases⁸³. The gut microbiota provides a powerful route that influences human health. In particular, polysaccharides and high fibre diet serve as primary modulators of the composition and role of the microbiota. The gut microbiota has been proposed as another factor involved in the onset of obesity. In a cohort study of 87 obese children and 57 healthy children, comparison of overall Faecal microbiota in obese children did not show variability in community diversity and richness⁸⁴. Probiotics exhibiting Bile salt hydrolase (BSH) activity can result in reduced bodyweight, also lower levels of plasma cholesterol and liver triglycerides concentration⁸⁵. The anti-obesity consequence of probiotic dark tea was assessed in high-fat diet fed Sprague-Dawley (SD) rats. Probiotic dark tea lowered the body weight rise, serum triglycerol levels and serum total glycerol levels in extraordinary fat diet SD rats⁸⁶. It is also shown that obesity is linked with increased Firmicutes, while the concentration of Bacteroidetes is reduced in obese patients⁸⁷. Obesity is associated with differentiation of preadipocytes to adipocytes which is examined by Lipid O staining. L. plantarum K10 isolated from homemade Kimchi showed 32.61% reduction in lipid accumulation compared to control. Freeze dried cultures of L. plantarum K10 fed to mice for 12 weeks demonstrated substantial drop in body weight as contrasted to high fat diet group⁸⁸. One of the approaches of probiotics employing antiobesity activity is inhibition of intestinal lipid absorption by exerting lipase inhibition. L. casei Q180 strain of human origin displayed a lipase repressive activity of 83.61±2.31% compared to control and prevention of adipocyte differentiation of 3T3-L1 cells⁸⁹. Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 given alone or in mixture for 9 weeks to mice were found to limit fat buildup in adipose tissue and liver⁹⁰. Many clinical trials proved use of probiotics in controlling obesity as shown in Table 2. Thus, probiotics not only play a positive role in physiology of the host but also plays a modulatory role in obesity. Probiotics have been shown to influence the gut composition, improve gut integrity and restore the normal flora disturbance which leads to obesity.

Table (2):
Clinical trials of probiotics in treatment of obesity.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein; BMI = Body mass index; SCFA, Short chain fatty acids; FFA = Free fatty acids.